Australia markets closed

Calidi Biotherapeutics, Inc. (CLDI)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
0.1900-0.1100 (-36.67%)
At close: 04:00PM EDT
0.1980 +0.01 (+4.21%)
Pre-market: 08:54AM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 9.68M
Enterprise value 20.25M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)50.83
Price/book (mrq)N/A
Enterprise value/revenue 49.42
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-98.17%
S&P500 52-week change 323.49%
52-week high 313.7900
52-week low 30.1440
50-day moving average 30.3270
200-day moving average 32.1096

Share statistics

Avg vol (3-month) 31.17M
Avg vol (10-day) 31.83M
Shares outstanding 550.92M
Implied shares outstanding 650.92M
Float 822.19M
% held by insiders 139.29%
% held by institutions 15.62%
Shares short (15 May 2024) 4295.05k
Short ratio (15 May 2024) 40.16
Short % of float (15 May 2024) 41.10%
Short % of shares outstanding (15 May 2024) 40.58%
Shares short (prior month 15 Apr 2024) 41.43M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-242.04%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -29.93M
Net income avi to common (ttm)-29.98M
Diluted EPS (ttm)-0.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.14M
Total cash per share (mrq)0.03
Total debt (mrq)11.51M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.13
Book value per share (mrq)-0.41

Cash flow statement

Operating cash flow (ttm)-27.71M
Levered free cash flow (ttm)-44.86M